Solid Tumor Unknown Status Phase 2 Trials for Sintilimab (DB15765)

Also known as: Cancer - Solid Tumors / Solid Tumour / Solid Tumours / Tumor, Solid / Solid Neoplasms / Solid tumour/cancer / Solid Cancers / Cancer: Solid Tumors / Neoplasms, Solid Tumor / Cancer, Solid Tumor / Tumors, Solid / Solid Tumor Cancer / Solid Tumors or Cancers / Solid Tumors / Solid Neoplasm / Cancer (Solid Tumors) / Solid Tumor Neoplasms / Solid Tumor Cancers / Solid Cancer / Neoplasm / Neoplasm (morphologic abnormality) / Neoplasms of unspecified behavior / Neoplasms NOS / Neoplasms NOS (disorder) / [M]Neoplasms NOS (morphologic abnormality) / Neoplasm (NOS) / Tumor / Neoplasm NOS / Tumour / Tumour NOS / Neoplasms / Tumour, NOS / Tumor NOS / Neoplasm, NOS / Tumor, NOS / Neoplasms benign, malignant and unspecified (incl cysts and polyps)

IndicationStatusPhase
DBCOND0030180 (Solid Tumor)Unknown Status2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT05322187
Sequential PD-1/PD-L1 Inhibitor and LENvatinib in TLCT and Refractory Hepatoblastoma After ChemotherapyTreatment
NCT05527821
Study of Surufatinib Combined With Sintilimab and SCRT in Advanced Solid TumorsTreatment
NCT05218148
SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric AdenocarcinomaTreatment